Vitrafy Life Sciences has formed a partnership with Hoxworth Blood Center to trial its red-cell cryopreservation technology, marking its second collaboration with a U.S. blood center following an earlier partnership with Vitalant. This pilot project aims to demonstrate the technology’s capabilities to extend red blood cell storage beyond traditional limits, which could significantly benefit emergency reserves and military supply chains. While Vitrafy reported a solid financial position with approximately $41.2 million in cash and deposits, this partnership is evaluative rather than commercial, with no confirmed revenue arrangements. Future milestones include installing the cryopreservation equipment at Hoxworth and obtaining validation for further commercialization. The company remains focused on expanding its U.S. presence amid competitive pressures in the blood preservation market.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://kalkine.com.au/news/healthcare/vitrafy-life-sciences-asxvfy-signs-hoxworth-blood-center-deal-as-us-red-cell-preservation-push-widens
